CRIS Curis Inc.

1.57
-0.02  -1%
Previous Close 1.59
Open 1.61
Price To book 26.17
Market Cap 225889959
Shares 143,878,955
Volume 1,100,668
Short Ratio 4.47
Av. Daily Volume 589,386

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171088020
  2. 8-K - Current report 171087999
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171083302
  4. 8-K - Current report 171083278
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171002809

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Poster presentation at ESMO September 11, 2017.
CA-170
Advanced solid tumor or lymphomas
Approved January 30, 2012.
Vismodegib
Basal Cell Carcinoma
Phase 2 initial data released August 3, 2017 - ORR 19%.
CUDC-907
Diffuse-large B-cell lymphoma (DLBCL)

Latest News

  1. Curis to Present at the Cantor Fitzgerald Global Healthcare Conference
  2. Why Curis Inc (CRIS) Could Be A Buy
  3. Curis Announces Pricing of Public Offering of Common Stock
  4. Curis Announces Proposed Public Offering of Common Stock
  5. Aurigene, a Wholly Owned Subsidiary of Dr. Reddy’s, and Curis Announce CA-170 Program Update Following Data Presented at ESMO 2017
  6. Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017
  7. Curis to Present at the Baird 2017 Global Healthcare Conference
  8. ETFs with exposure to Curis, Inc. : September 6, 2017
  9. Do Options Traders Know Something About Curis (CRIS) Stock We Don't?
  10. Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress
  11. ETFs with exposure to Curis, Inc. : August 25, 2017
  12. Curis, Inc. :CRIS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
  13. Edited Transcript of CRIS earnings conference call or presentation 3-Aug-17 12:30pm GMT
  14. Curis reports 2Q loss
  15. Here's Why Curis, Inc. Dropped as Much as 14.5% This Morning
  16. Curis Reports Second Quarter 2017 Financial Results
  17. Investor Network: Curis, Inc. to Host Earnings Call
  18. LD Micro Index Reconstitution as of August 1, 2017
  19. Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer
  20. Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171088020
  2. 8-K - Current report 171087999
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171083302
  4. 8-K - Current report 171083278
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171002809
  6. 8-K - Current report 171002769
  7. S-8 - Securities to be offered to employees in employee benefit plans 17902989
  8. 8-K - Current report 17896621
  9. 8-K - Current report 17860892
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17811900